Should You Take a GLP-1 Drug to Treat OSA?

Next up video playing in 10 seconds
Benefits of GLP-1s Beyond Weight Loss and Diabetes
Questions to Ask Your Doctor
Thinking about whether a GLP-1 is right for you to help treat your OSA? Here are the questions to ask your physician.
- Am I a good candidate to take Zepbound for OSA?
- What health conditions would disqualify me from taking Zepbound for OSA?
- How much weight would I need to lose to see an improvement in my nighttime breathing and daytime sleepiness?
- How long would I need to take Zepbound before I start noticing improvements with OSA?
- What are some side effects I might experience when taking Zepbound for OSA?
- How is Zepbound different from other standard OSA treatments?
- Would I be able to stop using a CPAP if my OSA symptoms get better with Zepbound?
- How will you keep track of whether my OSA symptoms are improving with Zepbound?
- Could Zepbound improve other aspects of my health, in addition to improving my OSA?
‘I Have OSA — Could I Benefit From Taking a GLP-1?’
While Zepbound has been shown to help people with OSA, this injectable medication specifically works for only a certain group of patients.
May Be a Good Fit For
- Adults who have been clinically diagnosed with moderate to severe OSA who have obesity
- Adults who have excess weight (overweight) and moderate to severe OSA, depending on the insurance
- Adults with moderate to severe OSA and obesity who have a hard time using the CPAP machine (For example, some people may have trouble falling asleep with a mask, while others might feel claustrophobic wearing the device.)
- Adults with moderate to severe OSA who have additional diseases or conditions associated with obesity, such as high blood pressure and type 2 diabetes, where a tirzepatide could also provide other benefits
May Not Be a Good Fit For
- Adults with mild OSA, as it has not been approved for this group
- Adults who have structural issues that may be causing OSA, such as a small jaw or enlarged tonsils
- Adults who are taking certain diabetes medications or birth control because the dosage may need to be adjusted while using this type of GLP-1 (Always discuss it with your doctor.)
Not a Good Fit For
- People under 18 who have OSA, as children are not approved to take Zepbound (the only FDA-approved GLP-1 for OSA)
- Adults who are pregnant, planning to become pregnant, or breastfeeding, which Zepbound is not approved for
- Adults who have a history of pancreatitis or a condition that might increase their risk of developing medullary thyroid carcinoma, a very rare thyroid cancer
- Patients with severe stomach or intestinal problems or active gallbladder disease
How GLP-1 Drugs Can Help With OSA
“We have known for years that with substantial weight loss following surgical intervention, such as the gastric sleeve or gastric bypass surgery, that patients have improvement and sometimes resolution of their OSA,” Ashraf says. “These medications offer a pathway without surgery to have clinically meaningful reduction in sleep apnea severity, and in some cases, they may resolve the OSA entirely,” Ashraf adds.
Are GLP-1 Drugs a Replacement for Other OSA Treatments?
Despite the clear benefits of Zepbound for OSA, this GLP-1 drug isn’t a replacement for conventional OSA treatment, including the CPAP machine. “I think of these treatments as addressing different aspects of OSA,” says Tu. For example, a CPAP machine can help you have better sleep right away (thanks to helping keep your airways open, which allows you to breathe freely). However, a patient on a tirzepatide may need 6 to 12 months on the medication before doctors see meaningful improvement in OSA severity, says Ashraf.
“Sleepiness symptoms and sleep disruption will improve faster with starting a CPAP than with weight loss, so I usually recommend patients start CPAP first or CPAP with tirzepatide,” says Ashraf. “But if a patient is very hesitant to start CPAP, we can start with focusing on weight reduction first,” says Ashraf. Also, reassessment is key. “After significant weight loss, repeat sleep testing can help determine whether OSA severity or PAP requirements have changed,” says Tu.
“Oftentimes, side effects improve after a couple of weeks, but if they do not, I recommend stopping the medication,” says Ashraf.
Finally, using Zepbound is not a quick fix for OSA. “It is also important to know there is a high likelihood that weight will return if the medication is stopped, even after dietary and lifestyle changes have been implemented,” says Ashraf. “I advise patients that we expect them to be taking this medication or another similar medication possibly for the rest of their life,” Ashraf adds.
- FDA Approves First Medication for Obstructive Sleep Apnea. U.S. Food and Drug Administration. December 20, 2024.
- Obstructive Sleep Apnea. Cleveland Clinic. December 4, 2024.
- Oral Appliance Therapy. American Academy of Dental Sleep Medicine.
- Continuous Positive Airway Pressure (CPAP). Mayo Clinic.
- Esmaeili N et al. The Relationship Between Obesity and Obstructive Sleep Apnea in Four Community-Based Cohorts: An Individual Participant Data Meta-Analysis of 12,860 Adults. eClinicalMedicine. May 2025.
- St-Onge MP et al. Weight Loss Is Integral to Obstructive Sleep Apnea Management. Ten-Year Follow-Up in Sleep AHEAD. American Journal of Respiratory and Critical Care Medicine. January 15, 2021.
- Dandamudi M et al. Efficacy of GLP-1 Receptor Agonists in Treating Obstructive Sleep Apnea: A Systematic Review and Meta-Analysis of Cardiometabolic and Respiratory Outcomes. Sleep and Breathing. April 24, 2026.
- CPAP Machines: Tips for Avoiding 10 Common Problems. Mayo Clinic. January 21, 2026.
- Consequences of Obesity. Centers for Disease Control and Prevention. July 9, 2026.
- Zepbound (Tirzepatide) Injection. U.S. Food and Drug Administration. January 2026.
- Obstructive Sleep Apnea. Zepbound. 2026.
- Understanding the Results. Harvard Medical School. April 16, 2021.
- Malhotra A et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. The New England Journal of Medicine. June 21, 2024.
- McCrimmon KK. What Is Zepbound? Does This Weight-Loss Drug Work Better Than Wegovy and Ozempic? UCHealth. May 18, 2026.
- Jiang Y et al. Why Does GLP-1 Agonist Combined With GIP and/or GCG Agonist Have Greater Weight Loss Effect Than GLP-1 Agonist Alone in Obese Adults Without Type 2 Diabetes? Diabetes, Obesity and Metabolism. March 2025.
- Lilly’s Tirzepatide Reduced Obstructive Sleep Apnea (OSA) Severity, With Up to 51.5% of Participants Meeting the Criteria for Disease Resolution. Lilly. June 21, 2024.
- Nutritional Priorities to Support GLP‐1 Therapy for Obesity: A Joint Advisory From the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity. August 2025.

Abhinav Singh, MD
Medical Reviewer
Abhinav Singh, MD, is a board-certified sleep medicine specialist and the medical director of the Indiana Sleep Center. He is also an associate clinical professor at Marian Univers...
